The present invention provides a hyperlipemia and/or hyperalbuminemia animal model that is useful for the development of preventive/therapeutic drugs for hyperlipemia and hyperalbuminemia, and in particular, that develops hyperlipemia and hyperalbuminemia at the stage of senility (advanced age) (in case of human, middle-aged and elderly). The hyperlipemia and/or hyperalbuminemia animal model is obtained by raising a transgenic rat (homozygote) into which a regucalcin gene is introduced and which overexpresses regucalcin to the stage of senility (advanced age), for example, 36 weeks of age, at which it exhibits symptoms of hyperlipemia and/or hyperalbuminemia. This animal model exhibits not only significant and marked increase of serum albumin, HDL-cholesterol and triglyceride concentrations but also bone disorders.